Journal of Antimicrobial Chemotherapy (2000) 45, 251-256
© 2000 The British Society for Antimicrobial Chemotherapy
Antimicrobial practice |
Antibiotic use in Dutch hospitals 1991–1996
a Maasland Ziekenhuis, Department of Clinical Pharmacy and Toxicology, PO Box 5500, 6130 MB Sittard; b University Hospital Nijmegen, The Netherlands and c Aberdeen Royal Hospitals, Aberdeen, UK
Abstract
The use of antibiotics in Dutch hospitals between 1991 and 1996 was investigated. A total of 54 hospitals responded to the enquiry, representing over 70% of all hospital beds in The Netherlands. The use of antibiotics in Dutch hospitals, expressed as defined daily doses (DDD) per hundred bed days, gradually increased from 37.2 DDD per 100 bed days in 1991 to 42.5 DDD per 100 bed days in 1996. The antibiotic that showed the largest increase in use was co-amoxiclav. Its use increased more than three-fold from 3.93 DDD per 100 bed days in 1991 to 12.5 DDD per 100 bed days in 1996. The increase in use of co-amoxiclav exceeded the increase in total antibiotic consumption. The use of cephalosporins remained fairly constant during the study period, but there were changes in the relative use of the different cephalosporin groups. The use of earlier cephalosporins gradually decreased, whereas the use of the more recently developed cephalosporins increased between 1991 and 1996. Ciprofloxacin and norfloxacin were the most commonly used fluoroquinolones throughout the study period. The use of ofloxacin increased significantly between 1991 and 1996, approaching the levels of use of ciprofloxacin and norfloxacin. There may be complex reasons for the increases, which need further analysis, but they mirror those few data available from elsewhere in the world. Possible explanations include more intensive treatment to expedite patient discharges, sicker patients with more serious infections and more resistant organisms.
Notes
* Corresponding author. Tel: +31-46-4597709; Fax: +31-46-4597971; E-mail: rjanknegt{at}capitolonline.nl
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Vaccheri, M. C. Silvani, L. Bersaglia, D. Motola, P. Strahinja, A. Vargiu, E. Poluzzi, and N. Montanaro A 3 year survey on the use of antibacterial agents in five Italian hospitals J. Antimicrob. Chemother., April 1, 2008; 61(4): 953 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Blix, A. Engeland, I. Litleskare, and M. Ronning Age- and gender-specific antibacterial prescribing in Norway J. Antimicrob. Chemother., May 1, 2007; 59(5): 971 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Curtis, J. Marriott, and C. Langley Development of a prescribing indicator for objective quantification of antibiotic usage in secondary care J. Antimicrob. Chemother., August 1, 2004; 54(2): 529 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. B. Wannet, E. Spalburg, M. E. O. C. Heck, G. N. Pluister, R. J. L. Willems, and A. J. de Neeling Widespread Dissemination in The Netherlands of the Epidemic Berlin Methicillin-Resistant Staphylococcus aureus Clone with Low-Level Resistance to Oxacillin J. Clin. Microbiol., July 1, 2004; 42(7): 3077 - 3082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Chopra and M. Roberts Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance Microbiol. Mol. Biol. Rev., June 1, 2001; 65(2): 232 - 260. [Abstract] [Full Text] [PDF]
|
|